Brandy N. Lepage

FDA investigator

Appears on 31 documents from 2021 to 2026, most often at sites in Pennsylvania. Most often cites production record review (21 CFR 211.192).

31
Documents on file
4.0
Observations per 483
2021
First seen
2026
Most recent

What they cite most

From 125 observations

Activity by year

2021: 6, 2022: 6, 2023: 6, 2024: 5, 2025: 4, 2026: 4

Where

Pennsylvania 8 · India 7 · New York 7 · Maryland 2 · Virginia 2 · Connecticut 1

Is Brandy N. Lepage coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

31 documents, newest first
FirmOpen
483 Emcure Pharmaceuticals LimitedMay 15, 2026 · Ahmedabad, India
483 Zydus Lifesciences LimitedMay 5, 2026 · Ahmedabad, India
483 Catalent Indiana LLCApr 24, 2026 · Bloomington, Indiana
483 Bora PharmaceuticalsMar 20, 2026 · Baltimore, Maryland
483 MSN Laboratories Private Limited Unit-05, Sy. Nos. (Parts of)7,8,13 andDec 11, 2025 · Farooqnagar Mandal, India
483 Apozeal Pharmaceuticals IncOct 15, 2025 · Levittown, Pennsylvania
483 Cosmetic Manufacturers (Aust) Pty Ltd.Apr 8, 2025

About this profile

What does Brandy N. Lepage inspect?

Brandy N. Lepage appears on 31 documents on file covering 30 sites, most often in Pennsylvania.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.67 and 21 CFR 211.160.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Brandy N. Lepage is dated May 15, 2026.